Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EBITDA (2016 - 2025)

Historic EBITDA for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to -$94.9 million.

  • Iovance Biotherapeutics' EBITDA fell 655.13% to -$94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$416.5 million, marking a year-over-year increase of 313.66%. This contributed to the annual value of -$395.3 million for FY2024, which is 1417.43% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported EBITDA of -$94.9 million as of Q3 2025, which was down 655.13% from -$113.8 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' EBITDA ranged from a high of -$86.6 million in Q4 2024 and a low of -$121.3 million during Q4 2023
  • Its 3-year average for EBITDA is -$107.8 million, with a median of -$110.9 million in 2023.
  • As far as peak fluctuations go, Iovance Biotherapeutics' EBITDA surged by 2860.06% in 2024, and later tumbled by 1163.73% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' EBITDA (Quarter) stood at -$121.3 million in 2023, then grew by 28.6% to -$86.6 million in 2024, then dropped by 9.62% to -$94.9 million in 2025.
  • Its EBITDA was -$94.9 million in Q3 2025, compared to -$113.8 million in Q2 2025 and -$121.2 million in Q1 2025.